Answers are grounded in this paper and cite their sources.
Biologic drugs account for a growing share of US pharmaceutical spending. Competition from follow-on biosimilar products (subsequent versions that have no clinically meaningful differences from the original biologic) has led to modest reductions in US health care spending, but these savings may not translate to lower out-of-pocket (OOP) costs for patients.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: